Oncolytics Biotech Inc T.ONC

ONCY Putting It's Best Foot Forward

[Proboscises]

The positive article released today (https://www.prnewswire.com/news-releases/rise-in-biotech-innovations-generating-hope-as-pancreatic-cancer-survival-rates-climb-301771271.html) which was paid for by ONC/Y as well as the intervew with Matt Coffey last week show continued eagerness by ONC/Y to promote the company.  I take this as a positive sign that ONC/Y management remains confident in pela and that they believe now (the next 6 months?) is the time for a deal with pharma.  

Some data will be revealed about BRACELET-1 when the ASCO abstracts are released online on April 26th.  However, the abstract submission deadline was Feb.14th so the April release may be somewhat dated, unless ONC/Y adds additional data at the late-breaking abstract submission deadline of March 16th.  ONC/Y has been focusing most attention on the data to be released at ASCO (June 2-6) which would be about 4 months more mature than the data from Feb 14th.  I expect positive results in the April 26th online abstract release, but even more compelling evidence to be revealed in early June.  We shall see.  ONC/Y seems to want to do all they can to put their best foot (i.e. best data) forward.

I think it is now evident that confidentiallity agreements with pharma companies recieving the BRACELET-1 data relates to the specifics of the BRACELET-1 data and the negotiating pharmas.   It does not relate to other information or trial results that ONC/Y is free to release or use to promote the company.

[Noteable]

ONCY is making an particular effort in getting the message out about the positive findings happening in the pancreatic cancer study, perhaps because these finding are being repeated as the data matures. 

[westcoast1000]

"I think it is now evident that confidentiallity agreements with pharma companies recieving the BRACELET-1 data relates to the specifics of the BRACELET-1 data and the negotiating pharmas.   It does not relate to other information or trial results that ONC/Y is free to release or use to promote the company." I was wondering about this point also. Thanks for clarifying your

[lonc17]

Everytime ONC pays for one of these "articles" it makes me respect them less.  A serious company with strong data coming in the near future would not have to sell themselves to penny-stock retal investors. Rather pathetic, really. 

[lonc17]

retail, not retal

[Noteable]

Every "respectable" company uses paid advertising to get its message out. Didn't you see the ads for Merck's Keytruda during the Academy Awards this weekend? Or those for Budweiser during the Superbowl? Or are you just too prudish to accept capitalism and the necessities that grease its wheels?

[Noteable]

See what a "respectable " company like Pfizer did to draw attention to it COVID-19 vaccine  .... https://endpts.com/pfizer-taps-pnk-michael-phelps-and-other-celebrities-in-latest-covid-campaign/ Pfizer put its best ideas forward .

[lonc17]

Paid advertising to promote a real product that is available for sale is entirely different from boiler-room activity intended to solicit money from naive investors in a weak effort to inflate a weak company's penny stock.

[lonc17]

If ONC was really, truly deep in negotiations with mulitple Big Pharmas and they really, truly see vast potential in the forthcoming data release, then there would be NO WAY AF that ONC would be spending money on boiler room phoney articles directed at naive millenial speculators.  This reeks of desparation and little more than a sorry effort to prop up the SP long enough to milk the ATM and

[lonc17]

Apologies for the spelling mistakes. I'm kind of ticked off after seeing these "paid for" news articles. 

[Lesalpes29]

Get the Word out again and again. If it's because of more results proving that we can be a player in panc cancer... why not ? It's probably part of the strategy to increase the visibility on the product and the results. GL

[fox7mf]

To me, and I'm bullish, seemingly being so close to the finish line & in serious multi party negotiations with much of the intended audience of these fluff pieces, now is not the right time to release one. It doesn't really inspire much confidence, and if the intended effect is to get the SP marching upwards, here's a better idea: NR's involving accelerated approval or priority

[Lesalpes29]

It's coming, it's next! Speculation only but pretty confident. 

[Capitalista]

Hey Fox:  to my memory (and this is admittedly anecdotal) these fluff pieces come out usually just before an NR directly from ONC/Y.  They may be intended to get prospective investors to put ONC/Y on their watch list so when the more meaty NR comes out, the shareprice pop is more dramatic. In any case - there was no effect from the most recent one.  That and the recent share price

[Lesalpes29]

Fluf piece, only asking myself if we are there anymore! Tend to think we are on the driver seat. Putting pressure on BP and help them to wake up! Speculation only again!

[westcoast1000]

I can readily see the viewpoints of Ionc and Fox.  Many of us have a great deal tied up here. But note the date: this piece came out in November, 2022. That was when the data first came out for the panc trial and before the Fast track designation. ONCY does need to try and keep the retail price up as much as possible as part of keeping the ship afloat from November until the negotiations